33rd Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 23.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING EDUCATION CREDIT (Pharmacists, Nurses, Nurse Practitioners, and Physician Assistants):
You will receive a certificate of attendance for the CME-certified sessions (those designated for AMA/PRA Category 1 Credits™) which may be submitted to state licensing boards for determination of credit reciprocity (conversion to CEUs).
Acknowledgment of Commercial SupportThis activity is supported by educational grants from Astellas, AstraZeneca, Boston Biomedical Pharma, Inc., Celgene Corporation, Clovis Oncology, Eisai Inc., Exelixis, Incyte Corporation, Ipsen Biopharmaceuticals, Inc., Lilly, Merck & Co., Inc., Merrimack Pharmaceuticals, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, Novocure, Pharmacyclics, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Puma Biotechnology, Taiho Oncology, Inc., and Takeda Oncology.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
The CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® is wholly owned and operated by PER Events, LLC, an affiliate of Physicians' Education Resource®.
Calendar of Events
Feb 28, 2017
Cancer Summaries and Commentaries™: Updates from Singapore: Advances in Personalized Lung Cancer Treatment
Feb 28, 2017